Skip to content
naulon
Get started

Not checked for notices yet.

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Jia Wei, Philippa C. Matthews, Nicole Stoesser and 19 more

Nature Communications · 2021

doi:10.1038/s41467-021-26479-2

References 57

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.
    Heterogeneity and longevity of antibody memory to viruses and vaccines · 2018
    No notice
  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.
    Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike · 2020
    Corrected
  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.
    Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison · 2020
    Corrected
  20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  21. 21.
    Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection · 2020
    No notice
  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.
    Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders · 2020
    Corrected
  24. 24.
    Robust neutralizing antibodies to SARS-CoV-2 infection persist for months · 2020
    No notice
  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.
    Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey · 2021
    No notice
  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.
    Anomalous collapses of Nares Strait ice arches leads to enhanced export of Arctic sea ice · 2021
    No notice
  38. 38.
    Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection · 2021
    No notice
  39. 39.
    Model-informed COVID-19 vaccine prioritization strategies by age and serostatus · 2021
    No notice
  40. 40.
    PRMT5 inhibition disrupts splicing and stemness in glioblastoma · 2021
    No notice
  41. 41.
    The antigenic anatomy of SARS-CoV-2 receptor binding domain · 2021
    No notice
  42. 42.
    Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
    No notice
  43. 43.
    Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 · 2021
    No notice
  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  47. 47.
    Association of Age With SARS-CoV-2 Antibody Response · 2021
    No notice
  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  53. 53.
    Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom · 2021
    No notice
  54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.